AAMDSIF is sharing this information to help you ensure your PNH patients on ULTOMIRIS or SOLIRIS receive uninterrupted treatment:

As of September 16, 2024, the separate ULTOMIRIS REMS and SOLIRIS REMS will be combined to harmonize vaccination data collection to mitigate risk of serious meningococcal infections across complement inhibitors.  This FDA mandated combined ULTOMIRIS and SOLIRIS REMS aims to strengthen patient safety standards and improve the REMS process for health care providers and patients. 

All prescribers, health care settings, and pharmacies must be recertified in the new, combined ULTOMIRIS and SOLIRIS REMS to receive and dispense product. 

For more information about recertification visit https://ultsolrems.com/